Experience using Imatinib and then Nilotinib, as second line, in patient with chronic myeloid leukemia and previous bariatric surgery. A case report

Centrone, Renato; Bellesso, Marcelo; Bonito, Debora; Dias, Daniela; Santucci, Rodrigo; Aranha, Milton; Alves, Adelson

Centrone, Renato; Bellesso, Marcelo; Bonito, Debora; Dias, Daniela; Santucci, Rodrigo; Aranha, Milton; Alves, Adelson.

Centrone, Renato; Instituto Hemomed de Oncologia e Hematologia. São Paulo. BR
Bellesso, Marcelo; Instituto Hemomed de Oncologia e Hematologia. São Paulo. BR
Bonito, Debora; Faculdade de Medicina do ABC. São Paulo. BR
Dias, Daniela; Instituto Hemomed de Oncologia e Hematologia. São Paulo. BR
Santucci, Rodrigo; Instituto Hemomed de Oncologia e Hematologia. São Paulo. BR
Aranha, Milton; Instituto Hemomed de Oncologia e Hematologia. São Paulo. BR
Alves, Adelson; Instituto Hemomed de Oncologia e Hematologia. São Paulo. BR

Hematol., Transfus. Cell Ther. (Impr.) ; 42(4): 373-375, Oct.-Dec. 2020. tab

Article in Spanish | LILACS | ID: biblio-1142970

Subject(s)

Humans; Female; Aged; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/therapy; Bariatric Surgery; Imatinib Mesylate/therapeutic use

Fulltext

XML

Search on Google

Full text: Available Index: LILACS (Americas) Main subject: Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Bariatric Surgery / Imatinib Mesylate Limits: Aged / Female / Humans Language: Spanish Journal: Hematol., Transfus. Cell Ther. (Impr.) Journal subject: Hematologia / TransfusÆo de Sangue Year: 2020 Type: Article Affiliation country: Brazil Institution/Affiliation country: Faculdade de Medicina do ABC/BR / Instituto Hemomed de Oncologia e Hematologia/BR

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

Search on Google